DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Court Improvement Program—New Grants.

OMB No.: 0970-0307.

Description: The President signed the Deficit Reduction Act of 2005 (DRA), Public Law 109–171, into law on February 8, 2006. The law authorizes and appropriates funds for two new grants under the Court Improvement Program in title IV–B, section 438, of the Social Security Act. The highest State

court in a State with an approved title IV–E plan is eligible to apply for either or both of the new grants. The new grants are for the purposes of (1) Ensuring that the needs of children are met in a timely and complete manner through improved case tracking and analysis of child welfare cases, and (2) training judges, attorneys, and other legal personnel in child welfare cases and conducting cross-training with child welfare agency staff and contractors.

The DRA requires separate applications for these two new grants. The annual burden estimates below describe the estimated annual burden for the two new grants. The Administration for Children and Families (ACF) proposes to collect

information from the States about their work under these grants (applications, program reports) by way of a Program Instruction that was issued on June 15, 2006. This Program Instruction described the programmatic and fiscal provisions and reporting requirements for each of the grants, specified the application submittal and approval procedures for the grants for fiscal years 2006 through 2010, and identified technical resources for use by State courts during the course of the grants. ACF will use the information received to ensure compliance with the DRA and provide training and technical assistance to the grantees.

Respondents: State courts.
Annual Burden Estimates:

Instrument	Number of respondents	Number of re- sponses per respondent	Average burden huors per response	Total burden hours
Application	52	2	40	4,160
	52	2	36	3,744

Estimated Total Annual Burden Hours: 7,904.

Additional Information: Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection. E-mail address: infocollection@acf.hhs.gov.

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the Federal Register.

Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Attn: Desk Officer for ACF, E-mail address:

Karen_Y._Matsuoka@omb.eop.gov.
Dated: November 21, 2006.

Robert Sargis,

Reports Clearance Officer.

[FR Doc. 06-9440 Filed 11-28-06; 8:45 am]

BILLING CODE 4184-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2005N-0097]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Experimental Study of Qualified Health Claims: Consumer Inferences About Monounsaturated Fatty Acids From Olive Oil, EPA and DHA Omega-3 Fatty Acids, and Green Tea

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Experimental Study of Qualified Health Claims: Consumer Inferences About Monounsaturated Fatty Acids From Olive Oil, [eicosapentaenoic acid] EPA and [docosahexaenoic acid] DHA Omega-3 Fatty Acids, and Green Tea" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT:

Jonna Capezzuto, Office of the Chief Information Officer (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827– 4659.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of May 22, 2006 (71 FR 29340), the agency announced that the

proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0592. The approval expires on November 30, 2009. A copy of the supporting statement for this information collection is available on the Internet at http://www.fda.gov/ohrms/dockets.

Dated: November 22, 2006.

Jeffrey Shuren,

Assistant Commissioner for Policy.
[FR Doc. E6–20200 Filed 11–28–06; 8:45 am]
BILLING CODE 4160–01–8

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Transmissible Spongiform Encephalopathies Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Transmissible Spongiform Encephalopathies Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on December 15, 2006, from 8 a.m. to 3:30 p.m.

Location: Crown Plaza Silver Spring, 8777 Georgia Ave., Silver Spring, MD. The hotel telephone number is 301–589–0800.

Contact Person: William Freas, or Rosanna L. Harvey, Center for Biologics Evaluation and Research (HFM–71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–0314, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014512392. Please call the Information Line for up-to-date information on this meeting.

Agenda: On December 15, 2006, the committee will discuss FDA's risk assessment for potential exposure to variant Creutzfeldt-Jakob disease in human plasma-derived antihemophilic factor (FVIII) products manufactured from U. S. plasma donors and related communication materials. In the afternoon, the committee will discuss levels of transmissible spongiform encephalopathy clearance in the manufacture of plasma-derived Factor VIII products. FDA intends to make background material available to the public no later than one business day before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at http:// www.fda.gov/ohrms/dockets/ac/ acmenu.htm, click on the year 2006 and scroll down to the appropriate advisory committee link.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before December 11, 2006. Oral presentations from the public will be scheduled between approximately 10:25 and 10:55 a.m. and 1:35 and 2:05 p.m. on December 15, 2006. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the

names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before December 7, 2006. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by December 8, 2006.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact William Freas or Rosanna L. Harvey at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: November 22, 2006.

Randall W. Lutter,

Associate Commissioner for Policy and Planning.

[FR Doc. E6–20251 Filed 11–28–06; 8:45 am] BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Statement of Organization, Functions and Delegations of Authority

This notice amends Part R of the Statement of Organization, Functions and Delegations of Authority of the Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA) (60 FR 56605, as amended November 6, 1995; 67 FR 46519, July 15,2002; and 68 FR 787–793, January 7, 2003; 68 FR 64357–64357, November 13, 2003; 68 FR 64357–64357–64358, and as last amended at 70 FR 42347–42348, July 22, 2005.)

This notice reflects organizational changes in the Health Resources and Services Administration, Bureau of Primary Health Care (RC). Specifically, this notice updates the functional statements of the Bureau of Primary Health Care.

Chapter RC—Office of the Associate Administrator

Section RC-10, Organization

Delete in its entirety and replace with the following: The Bureau of Primary Health Care (BPHC) is headed by an Associate Administrator, who reports directly to the Administrator, Health Resources and Services Administration. The Bureau of Primary Health Care includes the following components:

- (1) Office of the Associate Administrator (RC);
- (2) Office of Minority and Special Populations (RCG);
- (3) Office of Policy and Program Development (RCH);
 - (4) Office of Quality and Data (RCK);
- (5) Office of Administrative Management (RCM);
 - (6) Eastern Division (RCN);
- (7) Central Mid-Atlantic Division (RCP);
 - (8) Western Division (RCQ);
- (9) Division of National Hansen's Disease Programs (RC7); and
- (10) Division Immigration Health Service (RC9).

Section RC-20, Functions

(1) Delete the functional statement for the Office of the Associate Administrator (RC) and replace in its entirety; (2) Establish the Office of Administrative Management (RCM); (3) Delete the Division of Health Center Management (RCJ) in its entirety and replace with the following new Divisions: Eastern Division (RCN), Central Mid-Atlantic Division (RCP), and Western Division (RCQ); (4) Delete the Division of State and Community Assistance (RCL) in its entirety; (5) Retitle the Division of Policy and Development (RCH) as the Office of Policy and Program Development (RCH) and replace its functional statement in its entirety; (6) Re-title the Division of Clinical Quality (RCK) as the Office of Quality and Data (RCK) and replace its functional statement in its entirety; and (7) Delete the functional statement for the Office of Minority and Special Populations (RCG) and replace in its entirety.

Office of the Associate Administrator (RC)

Provides overall leadership, direction, coordination, and planning in support of Bureau programs: (1) Establishes program goals, objectives and priorities, and provides oversight as to their execution; (2) plans, directs, coordinates and evaluates Bureau-wide management activities; and (3) maintains effective relationships within HRSA and with other Department of Health and Human